SG293 represents a differentiated in vivo CAR T cell approach designed to work without lymphodepletion to deliver potent therapeutic activity and exceptional specificity to minimize off-target effects ...
Interim results from SIDNEY Phase 2 trial show EO2463 rapidly induced extensive in vivo expansion of B cell target-specific CD8 ...
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and ...
Data from pivotal Phase 3 frontMIND trial evaluating tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) selected for prestigious Plenary Abstracts SessionOral and ...
Urban China is expected to lead globally in diagnosed PCNSL cases in 2024 and 2029. Current treatment relies on off-label use and BTK inhibitors, but there's a significant unmet need driving ...
LUND, SE / ACCESS Newswire / May 12, 2026 / BioInvent International (STO:BINV) - BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory ...
SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported ...
A new computational method could dramatically accelerate efforts to map the body's cells in space, according to a study ...
Living tissues do not change through biology alone. They are shaped by a constant dialogue among forces, chemicals, and ...
BioOra Limited, a New Zealand-based company pioneering automated, cost-effective CAR T-cell manufacturing, today announced ...
In a finding that challenges decades of assumptions about blood cancer, an international research team has shown for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results